Neurogene
NGNE
36 hedge funds and large institutions have $38.3M invested in Neurogene in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 14 closing their positions.
66% more call options, than puts
Call options by funds: $121K | Put options by funds: $73K
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0.11% less ownership
Funds ownership: 3.88% → 3.77% (-0.11%)
20% less funds holding
Funds holding: 45 → 36 (-9)
28% less capital invested
Capital invested by funds: $53.5M → $38.3M (-$15.2M)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$671K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$534K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$268K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$182K |
| 5 |
EP
Eversept Partners
New York
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$1.47M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$482K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
-$293K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$273K |
| 5 |
Millennium Management
New York
|
-$267K |
NGNE Hedge Fund Activity: Q4 2018 in Review
36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2018, worth a combined $38.3M — down 28% from $53.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NGNE and 6 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Highbridge Capital Management, adding an estimated $671K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.47M sold.
- 36 institutional investors held Neurogene (NGNE) as of Q4 2018, down from 45 in Q3 2018.
- Funds reported $38.3M of Neurogene stock for Q4 2018, down 28% quarter-over-quarter.
- 6 funds opened new Neurogene positions in Q4 2018 and 14 closed out, a net change of -8 holders.
- The largest Neurogene buyer in Q4 2018 was Highbridge Capital Management, an estimated $671K added.
- The largest Neurogene seller in Q4 2018 was Ghost Tree Capital, an estimated $1.47M sold.
Based on aggregated 13F filings for Q4 2018.